semaglutidedulaglutide
…intensification or change was 1.6 (0.7) and 1.4 (0.7) years for semaglutide and alternative treatment, with no subgroup differences noted (…
7articles mentioning drugs
25drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: SGLT-2 inhibitors ×
SGLT-2 inhibitors
This drug is selected. Its supporting articles are shown below.
Articles mentioning SGLT-2 inhibitors
7 articles · page 1 of 1sulfonylureasSGLT-2 inhibitorssodium-glucose cotransporter-2 (SGLT-2) inhibitorsherpes zosterautoimmune rheumatic diseasestype 2 diabetesinflammatory arthritis
…es: 552 065 initiated SGLT-2 inhibitors and 1 480 092 initiated sulfonylureas.Main outcome measures The primary outcome was autoimmune rheuma…
SGLT-2 inhibitorsSGLT2-inhibitorsCOPDheart failureDiabetesacute ischaemic heart disease
…esenting 1197 admissions, were identified. 32 patients received SGLT-2 inhibitors. Those receiving SGLT-2 inhibitors were associated with a 26% r…
tirzepatidefinerenoneGLP-1 receptor agonistsSGLT-2 inhibitorstype 2 diabetesCKD
…tes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide):• Lower risk (three or fewer cardiovascular risk factors witho…
Sodium-glucose co-transporter 2 (SGLT-2) inhibitorsSGLT-2 inhibitorskidney diseaseheart failureSandwell and West Birmingham Hospitals NHS Trusthypoglycaemia
…Background Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are originally anti-diabetic agents which have also important c…
91.8%
Metformininsulin-treatedSGLT-2 inhibitorsHbA1cstatinsGLP-1 receptor agonistsinsulin analogsinsulinT2Dtype 2 diabetes+1 more
…excluded to minimize misclassification of gestational diabetes. Metformin dispensations alone before age 40 were disregarded in women wit…
83.8%
EntrestoBeta BlockersSGLT-2 Inhibitorscancer therapyQueen Elizabeth Hospitalhaematological malignancyIBM CorpEuropean Society of Cardiology
…of ACE-Inhibitors / ARBs, Beta Blockers, SGLT-2 Inhibitors, and Entresto at follow-up, compared to baseline (* = p-value < 0.05). ACE-I,…